MSH and MIF-I in animal models of tardive dyskinesia.
alpha-Melanocyte stimulating hormone (MSH) and MSH release inhibiting factor (MIF-I) were tested for their effects on animals with prior exposure to haloperidol. Such animals are known to have an augmented sterotypic response to dopamine agonists and have been used as an animal model of tardive dyskinesia. Both MSH and MIF-I increased the stereotypy that followed the administration of the lowest dose of apomorphine (0.125 mg/kg), suggesting that MSH and MIF-I might weakly increase dopaminergic transmission.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000503:physiopathology*; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D009075:MSH Release-Inhibiting Hormone / Q000494:pharmacology*; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects
D009074:Melanocyte-Stimulating Hormones; D009075:MSH Release-Inhibiting Hormone; D006220:Haloperidol; D001058:Apomorphine